Biomm

Biomm launches the *Viva sua Maternidade* program to support pregnant employees and their families.

Biomm partners with Bioeq AG to distribute Ranibizumabe (BQ201) in Brazil, a biosimilar medication produced in Switzerland.

Biomm partners with CanSino Biologics to supply Convidecia, a COVID-19 vaccine, to Brazil’s national immunization program.

Biomm introduces flexible work schedules and anniversary leave as new employee benefits starting April.

Biomm seeks qualified professionals to join key areas, supporting its mission to improve health access.

Biomm opens new job opportunities in Nova Lima for professionals across fields and experience levels in the pharmaceutical sector.

The Projetecno training program teaches Biomm’s logistics team safe forklift operation to prevent accidents and improve efficiency.

The page explains Biomm’s business flowchart, detailing departments, internal and external processes, and their connections. Katia Beltrão discusses the role of Marketing.

The page outlines Biomm’s business flowchart, detailing departments, processes, and their connections. Caio Campos and Carla Miranda explain their department’s role.

The page covers the first 2023 edition of Biomm’s CEO conversation, which discussed fourth-quarter 2022 results, the 2022 consolidated cycle, and the implementation of internal culture.

The page discusses how company culture is built through daily practices of values, strategies, behaviors, and policies. Daniele Galina explains the topic.

Biomm secures a **R$131 million contract** with Fiocruz to supply insulin under a **10-year agreement**, reinforcing Brazil’s push for domestically produced pharmaceuticals. The deal focuses on **glargine insulin**, a long-acting diabetes treatment, and may encourage broader market adoption of safer alternatives. This partnership aligns with Brazil’s industrial health policy goals, potentially reshaping the country’s insulin supply chain.

Nov 2025Brazil Stock GuideNews article

Biocon partners with Biomm to commercialize a diabetes drug in Brazil. Biomm operates a production facility in Nova Lima, specializing in biotech and biosimilar drug development and manufacturing. The collaboration aims to bring advanced pharmaceutical solutions to the Brazilian market.

Apr 2024Zee BusinessNews article

MannKind Corporation’s inhaled insulin powder **Afrezza** secures pricing approval in Brazil from the Chamber of Regulation of the Medicines Market (CMED). Local partner **Biomm S.A.** now begins commercial distribution nationwide, with sales launching the week of January 13, 2020. The product offers an alternative insulin delivery method for diabetes management.

Jan 2020nasdaq.comNews article

MannKind Corporation’s Afrezza, an insulin human inhalation powder, receives regulatory approval in Brazil. The product delivers insulin via the lungs, leveraging their extensive surface area for rapid absorption. Afrezza provides an alternative administration method for diabetes management.

Jun 2019MannKind CorporationNews article